CN Patent

CN103420977B — 具有抗肿瘤活性的乙炔衍生物

Assigned to Shanghai Pharmaceuticals Holding Co Ltd · Expires 2016-06-22 · 10y expired

What this patent protects

本发明涉及具有通式I的芳香环二取代乙炔衍生物，包含该化合物的药物组合物，以及该化合物和药物组合物用于治疗和/或预防肿瘤的用途，其中A、B、T、M、Ra、Rb、Rt、m、n和p如本文所定义。

USPTO Abstract

本发明涉及具有通式I的芳香环二取代乙炔衍生物，包含该化合物的药物组合物，以及该化合物和药物组合物用于治疗和/或预防肿瘤的用途，其中A、B、T、M、Ra、Rb、Rt、m、n和p如本文所定义。

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN103420977B
Jurisdiction: CN
Classification: —
Expires: 2016-06-22
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Pharmaceuticals Holding Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.